INTRODUCTION {#S1}
============

Fragile X syndrome (FXS) is characterized by intellectual disability, developmental delays, social impairment, and other maladies. The cause of FXS is an iteration of \~200 or more CGG triplets in *FMR1* that induces DNA methylation and transcriptional inactivation. Loss of the *FMR1* gene product FMRP results in synaptic dysfunction and aberrant circuit formation, which produces neuro-pathological conditions during development ([@R70]). FXS is modeled in *Fmr1* knockout (KO) mice, which mimic many facets of the human disease, including learning and memory deficits, repetitive disorders, and susceptibility to seizures. In these animals, neuronal communication is frequently examined at hippocampal Schaffer collateral-CA1 synapses, which exhibit exaggerated metabotropic glutamate-receptor-dependent long-term depression (mGluR-LTD) ([@R30]). This form of synaptic plasticity normally requires protein synthesis, but in *Fmr1*-deficient animals, protein synthesis is both unnecessary for mGluR-LTD and excessive in neurons, which contributes to aberrant circuit formation and other hallmarks of the syndrome ([@R85]).

FMRP is an RNA-binding protein present in most cells; in neurons, its localization at postsynaptic sites is thought to control activity-dependent synapse remodeling by regulating mRNA expression ([@R67]). Considerable effort has been made to identify FMRP target mRNAs, but the most rigorous involves *in vivo* crosslink and immunoprecipitation (CLIP). CLIP combined with RNA sequencing (RNA-seq) has identified 842 target mRNAs in the post-natal day 11 (P11)--P25 mouse cortex and cerebellum ([@R10]); predominantly a single mRNA in cultured cortical neurons ([@R77]); 1,610 RNAs in the P13 cortex, hippocampus, and cerebellum ([@R55]); and \~6,000 RNAs in HEK cells expressing epitope-tagged FMRP ([@R3]). This diversity of FMRP CLIP targets could reflect the different procedures employed or the different brain cell types examined. Surprisingly, the majority of CLIP sites in mRNA are in coding regions ([@R10]; [@R55]), with a bias to some *cis* sequences ([@R2]; [@R55]). FMRP association with mRNA coding regions and co-sedimentation with polyribosomes ([@R39]; [@R16]; [@R75]) suggests it normally inhibits translation by impeding ribosome translocation. Indeed, studies that examined polypeptide elongation ([@R80]) or susceptibility to puromycin release of nascent polypeptides ([@R10]) indicate that FMRP regulates ribosome transit. Supporting evidence comes from studies showing that *Drosophila* FMRP interacts with ribosomal protein L5 ([@R37]), which may preclude tRNA or elongation factors from engaging the ribosome and causing it to stall ([@R7]). Although these observations need to be extended to mammalian FMRP, they suggest a molecular mechanism by which FMRP stalls ribosomes. Such observations do not indicate how FMRP could stall ribosomes on specific mRNAs.

Ribosome profiling is a whole-transcriptome method for analyzing the number and positions of ribosomes associated with mRNA; when combined with RNA-seq, it yields heretofore unobtainable information on gene expression at high resolution ([@R34]; [@R33]; [@R5]). We used ribosome profiling to explore FMRP regulation of gene expression in mouse adult neural stems cells (aNSCs), which in FXS have a proclivity to differentiate into glia at the expense of neurons ([@R50]; [@R53]; [@R26]). We identified mRNAs whose ribosome occupancy was either up or downregulated in FMRP-deficient cells or had altered steady-state levels reflected by their association with ribosomes. We identified yet additional mRNAs whose ribosome occupancy was "buffered" so that changes in their levels were compensated for by opposite changes in ribosome association ([@R50]).

Ribosome profiling at steady state cannot distinguish between translocating and stalled ribosomes, suggesting that studies examining FMRP-regulated translation by this method or translating ribosome affinity purification (TRAP) and RNA-seq (TRAP-seq) ([@R78]; [@R50], [@R51]; [@R23]; [@R11]) may overlook key events leading to FXS. Moreover, if intact brain circuitry is important for FMRP regulation, then cultured neurons might not reveal important aspects of FMRP function. To circumvent these issues, we have developed a hippocampal slice assay to detect mRNA-specific ribosome translocation dynamics. Hippocampal slices maintain the *in vivo* synaptic connectivity and cellular architecture and express protein synthesis and FMRP-dependent forms of synaptic plasticity ([@R30]). Profiling over a time course of ribosome runoff in slices demonstrates a wide range of ribosome translocation rates on specific mRNAs, from rapid (rates similar to those in embryonic stem \[ES\] cells; [@R35]) to near-complete stalling. Many mRNAs retain 4--6 ribosomes after runoff in wild-type (WT), but not in FMRP-deficient, slices. Some RNAs associated with FMRP-stalled ribosomes encode proteins involved in neurologic function and transcriptional regulation. One such RNA encodes SETD2, a methyltransferase for the chromatin mark H3K36me3. We find increased SETD2 protein in *Fmr1*-deficient hippocampus. Chromatin immunoprecipitation sequencing (ChIP-seq) demonstrates that distribution of this mark varies in a genotype (i.e., WT versus *Fmr1*-deficient)-dependent manner in hippocampal tissue. In mammals, apart from blocking cryptic transcription initiation and DNA damage response, H3K36me3 is correlated with pre-mRNA processing events such as alternative splicing ([@R41]; [@R42]). RNA-seq reveals that splicing events such as exon skipping are altered in FMRP-deficient slices and that these transcripts are linked to neural function and autism spectrum disorders. Aberrant RNA splicing of synapse related genes is prevalent in autism spectrum disorders ([@R48]; [@R63]; [@R74]). Our study demonstrates that a reduction in ribosome stalling in the *Fmr1*-deficient brain results in a cascade of epigenetic and RNA processing changes that likely contribute to neurologic disease.

RESULTS {#S2}
=======

Hippocampal Schafer collateral-CA1 synapses exhibit an exaggerated mGluR-LTD in *Fmr1*-deficient mice that is aberrantly protein-synthesis independent ([@R58]; [@R31]). To identify mRNAs whose basal expression is misregulated, we prepared CA1-enriched hippocampal slices (400 μm) ([Figure 1A](#F1){ref-type="fig"}), performed ribosome profiling and RNA-seq ([Figure 1B](#F1){ref-type="fig"}), and calculated translational efficiency (TE), the ratio of ribosome footprints to RNA-seq reads. We identified RNAs with changes in TE (TE up/TE down) or RNAs whose levels were elevated or reduced but without changes in TE (mRNA up/mRNA down) ([Figure 1C](#F1){ref-type="fig"}; [Table S1](#SD2){ref-type="supplementary-material"}) (nominal p value \< 0.01, false discovery rate \[FDR\] = 0.097 by permutation test). A Gene Ontology (GO) analysis of the biological processes most enriched in each group shows that the mRNA-down group encodes factors that mediate taxis/chemotaxis, while the mRNA-up group encodes factors involved in ribonucleotide metabolism ([Figure 1D](#F1){ref-type="fig"}, [S1A](#SD1){ref-type="supplementary-material"}, and [S1B](#SD1){ref-type="supplementary-material"}). The TE-down mRNAs encode factors that control synaptic transmission ([Figures 1D](#F1){ref-type="fig"} and [S1C](#SD1){ref-type="supplementary-material"}). The mRNA-down group is enriched for cellular components linked to the extracellular matrix, while the mRNA-up group encodes the myelin sheath and spliceosome-interacting factors. The TE-down group is involved in the extracellular matrix and synaptic architecture ([Figures 1E](#F1){ref-type="fig"} and [S1C](#SD1){ref-type="supplementary-material"}). No GO terms from the TE-up group were statistically significant.

Heatmaps of the top 20 mRNAs with altered up and down TEs in *Fmr1-*deficient slices compared to the WT are shown in [Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}. Examples of the change in TEs are depicted in [Figures 2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}. *Gfpt2* (glutamine-fructose-6-phosphate transaminase 2) mRNA is nearly unchanged in *Fmr1* KO but has an increase in ribosome footprints; [Figure 2C](#F2){ref-type="fig"}). Conversely *Lhfpl5* (lipoma high-mobility group protein isoform C \[HMGIC\] fusion partner-like 5) mRNA has reduced numbers of ribosome footprints while RNA levels are mostly unchanged ([Figure 2D](#F2){ref-type="fig"}). Neither *Gfpt2* nor *Lhfpl5* mRNAs have FMRP CLIP sites. [Figure 2E](#F2){ref-type="fig"} shows boxplots for all 843 FMRP CLIP RNAs (p value \< 0.0001, Wilcoxon test) ([@R10]). As a group, these RNAs decrease significantly in *Fmr1* KO, which is tracked by commensurate decreases in ribosome footprints resulting in no change in TE.

We compared our TE-down and TE-up groups in *Fmr1* KO hippocampus with results from [@R11], who performed ribosome profiling on mouse frontal cortex, and [@R78], who performed TRAP-seq from hippocampal CA1 pyramidal neurons ([Figure 2F](#F2){ref-type="fig"}). Only 37 of our TE-down RNAs were detected by [@R11] (\~7% overlap), and only 5 were detected by [@R78] (\~17% overlap). Even fewer of our TE-up RNAs were detected in either of those studies ([Figure 2F](#F2){ref-type="fig"}) (\~2% overlap). We surmise that the differences in methods and source material are likely responsible for little overlap among the studies.

Our data show almost all changes in ribosome footprint number in *Fmr1*-deficient slices can be attributed to altered RNA levels irrespective of whether the transcripts are FMRP CLIP targets. This suggests that the increase in incorporation of labeled amino acids into protein in *Fmr1* KO hippocampal slices (e.g., [@R14]; [@R80]; [@R4]) is mostly due to changes in RNA levels and/or ribosome transit rate. However, TE may not necessarily reflect protein production. For example, increased initiation with no change in elongation would produce increased ribosome footprints and yield an elevated level of protein product ([Figure 2G](#F2){ref-type="fig"}). If there is no change in initiation but elevated elongation, the TE will appear to be reduced but the production of protein will be increased. Consequently, ribosome profiling at steady state, which cannot distinguish between transiting and stalled ribosomes, may inadequately represent translation if there are changes in elongation. To assess whether FMRP regulates ribosome dynamics, we modified our procedure to investigate temporal changes in transcriptome-wide ribosome translocation rates.

Ribosome Runoff Dynamics in Hippocampal-Cortical Slices {#S3}
-------------------------------------------------------

We next performed ribosomal profiling and RNA-seq in hippocampal-cortical slices at different time points after blocking initiation with homoharringtonine (HHT). HHT halts ribosomes on initiation codons but allows elongating ribosomes to continue translocating until they run off ([@R35]; [@R49]). We aimed to determine differences in ribosome translocation rates of all expressed genes in WT tissue slices. Slices were incubated with HHT for 0--60 min and ribosome transit stopped at specific times with cycloheximide; the samples were then used for ribosome profiling ([Figure 3A](#F3){ref-type="fig"}; [Table S1](#SD2){ref-type="supplementary-material"}). A metagene analysis of the ribosome footprints on 1,401 mRNAs with open reading frames (ORFs) of \>3,000 nt aligned with the start and stop codons is shown in [Figure 3B](#F3){ref-type="fig"}, indicating that the ribosomes runoff in a 5′→3′ direction. We chose mRNAs with ORFs \>3,000 nt to ensure that ribosome runoff was not complete within 10 min of HHT treatment and read densities could be obtained at each nucleotide position. The read densities were normalized to the average densities of the last 500 nt of the protein coding sequence (CDS) and is based on the P site of the ribosome footprints. A linear regression analysis between the HHT treatment time and ribosome runoff distances was then used to estimate a global elongation rate of 4.2 nt/s at 30°C ([Figure 3C](#F3){ref-type="fig"}). By comparison, the global elongation rate in cultured ES calls is 1.7 nt/s at 37°C ([@R35]).

We performed a cluster analysis of all mRNAs with respect to number of ribosome-protected fragments (RPFs) at each time point relative to time 0. Briefly, Euclidean distance was first computed, followed by hierarchical clustering using Ward's algorithm ([@R84]), and the analysis of group similarities (ANOSIM) test ([@R8]) was then used to assess whether distances between clusters were statistically greater than within clusters ([Figure 3D](#F3){ref-type="fig"}). The mRNAs fell into two broad clusters (ANOSIM R = 0.56, p value \< 0.001): those whose ribosome runoff occurred relatively quickly (i.e., within 5--10 min, bottom cluster), and those whose runoff occurred slowly, if at all (top cluster). These two clusters were further grouped into three sub-clusters each for six total subclusters (ANOSIM R = 0.64, p \< 0.001). Subclusters 1--3 had slow runoff times, while subclusters 4--6 had relatively fast ribosome runoff times ([Figures 3D](#F3){ref-type="fig"} and [3E](#F3){ref-type="fig"}). The ribosomes on mRNAs in subcluster 2 had the slowest runoff time. We determined the ribosome runoff patterns for the mRNAs in each subcluster ([Figure 3E](#F3){ref-type="fig"}). For example, mRNAs for Alcam (activated leukocyte cell adhesion molecule), Arc (activity-regulated cytoskeleton), and Nptn (neuroplastin) are present in subcluster 1, Col11 (collectin subfamily 11) in subcluster 2, Nrxn3 (neurexin 3) in subcluster 3, and actin in subcluster 4 ([Figure 3F](#F3){ref-type="fig"}). As examples, [Figure 3G](#F3){ref-type="fig"} shows the ribosome footprints of Nrxn3 and actin over time; [Figure S2A](#SD1){ref-type="supplementary-material"} shows ribosome footprints for additional mRNAs. Although there was some CDS-length dependency of the ribosome runoff rates, the correlation was not linear ([Figure S2B](#SD1){ref-type="supplementary-material"}). GO term analysis showed that specific biological activities were associated with each subcluster. Genes in subclusters 1 and 3 (slow runoff times) were associated with neural function such as axon development and synapse organization ([Figure 3H](#F3){ref-type="fig"}). Subcluster 2, which contained ribosomes with the slowest runoff rates, had genes encoding the extracellular matrix; subcluster 4 contained genes involved in metabolic functions; subcluster 5 was associated with mRNA processing and regulation; and subcluster 6 was associated with organelle localization ([Figure S2C](#SD1){ref-type="supplementary-material"}). These results suggest that clusters of mRNAs with specific functions have differential ribosomal transit rates.

FMRP Controls Ribosome Translocation on Specific mRNAs {#S4}
------------------------------------------------------

To investigate whether FMRP controls ribosome stalling on specific mRNAs, we first determined whether it is present in ribosome-containing complexes ([@R16]; [@R40]; [@R75]; [@R15]). Extracts from cortices were treated with nonionic detergent (NP40) in the presence or absence of RNase and sedimented through sucrose gradients. [Figure S3A](#SD1){ref-type="supplementary-material"} shows FMRP sedimented to a "heavy" ribosome-containing region of the gradient ([@R75]; [@R10]). These data suggest that FMRP is associated with ribosomes in heavy fractions and thus could play a role in ribosome stalling.

We next performed sucrose gradient analysis of slices treated with HHT for 30 min ([Figure 4](#F4){ref-type="fig"}), which allows ribosomes on most genes to run off (cf. [Figure 3](#F3){ref-type="fig"}). [Figure 4A](#F4){ref-type="fig"} shows that most FMRP co-sediments with polysomes as shown previously (e.g., [@R16]; [@R75]), but after HHT treatment, it is more prevalent in "medium" gradient fractions that correspond to four to six ribosomes most likely due to association with stalled ribosomes. Other proteins (e.g., UPF1, MAP2, and eEF2) do not show a similar change in sedimentation ([Figure S3B](#SD1){ref-type="supplementary-material"}). A small amount of FMRP remains in a heavy (\>7 ribosomes) region of the gradient ([Figure 4B](#F4){ref-type="fig"}). The same experiments were performed with *Fmr1* KO slices ([Figures 4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}). RNA-seq of the heavy fractions showed that 1,574 RNAs and 686 RNAs were reduced or elevated, respectively, in both genotypes, indicating a sensitivity or resistance to HHT treatment ([Figure 4E](#F4){ref-type="fig"}). *Actin* is one RNA that was sensitive to HHT and was depleted by ribosome runoff ([Figure 4F](#F4){ref-type="fig"}), which is consistent with results from the HHT time course ([Figures 3F](#F3){ref-type="fig"} and [3G](#F3){ref-type="fig"}). *Map1b* RNA, on the other hand, was enriched in the heavy polysomes by HHT treatment ([Figure 4G](#F4){ref-type="fig"}). [Figure 4H](#F4){ref-type="fig"} shows GO terms for the RNAs depleted in the heavy fractions after runoff, which include factors involved in RNA metabolism. [Figure 4I](#F4){ref-type="fig"} shows GO terms for RNAs enriched in the heavy polysomes after HHT treatment, which include factors involved in membrane and ion transport.

In contrast to the heavy polysome fractions, we found genotype-specific differences in the RNA-seq of the medium polysome fractions ([Table S1](#SD2){ref-type="supplementary-material"}). Forty-six RNAs were downregulated in HHT-treated *Fmr1* KO slices relative to WT, indicating that they are normally bound by FMRP-stalled ribosomes ([Figure 5A](#F5){ref-type="fig"}). Eight of these mRNAs encode chromatin and transcriptional regulators, and 23 encode proteins involved in neural function ([Figure 5B](#F5){ref-type="fig"}). One is *Ankrd12* (ankyrin repeat domain containing 12), which is depleted in the KO slices following HHT treatment ([Figure 5C](#F5){ref-type="fig"}). [Figure 5C](#F5){ref-type="fig"} shows that after HHT treatment, *Ankrd12* RNA contains fewer stalled ribosomes in the medium fractions of *Fmr1* KO slices, confirming this mRNA is under FMRP regulation. [Figure 5D](#F5){ref-type="fig"} demonstrates that compared to all RNAs, the HHT-sensitive RNAs ([Figure 5B](#F5){ref-type="fig"}) showed significant decreases in RPFs and TEs, but not RNA levels, in *Fmr1* KO relative to WT (ribosome profiling data of these RNAs from [Figure 2](#F2){ref-type="fig"}; \*\*p \< 0.01; \*\*\*p \< 0.001, Wilcoxon test) showing the consistency between steady-state ribosome profiling and the dynamic ribosome runoff assay.

Finally, [Figure 5E](#F5){ref-type="fig"} demonstrates that one of the mRNAs decreased in the medium fraction in the *Fmr1* KO slices, *SETD2*, shows an increase in its protein level in *Fmr1* KO hippocampus relative to WT (p = 0.0245, two-tailed t test), which is expected if FMRP stalls ribosome translocation on this RNA. We find no statistically significant increase in SETD2 mRNA in RNA-seq data from the FMRP KO hippocampal slices (from [Figure 1](#F1){ref-type="fig"}). We tested SETD2 protein in immortalized mouse embryonic fibroblasts (MEFs) derived from WT and *Fmr1* KO mice and found no change relative to genotype ([Figure S5E](#SD1){ref-type="supplementary-material"}). This result might reflect a possible brain-specific function of FMRP or that rapidly dividing MEF cell lines do not recapitulate FMRP-dependent ribosome stalling, at least not on SETD2 mRNA. SETD2 is the main histone lysine methyltransferase that trimethylates the histone H3 tail on the lysine36(K36).

FMRP-Mediated Regulation of H3K36me3 {#S5}
------------------------------------

To investigate whether altered SETD2 levels influence gene-specific changes in H3K36me3, we performed ChIP-seq from WT and *Fmr1* KO hippocampus in duplicate, combining hippocampal tissue from two animals per biologic replicate ([Figure 6A](#F6){ref-type="fig"}). All genotypic replicates were highly correlated with each other([Figure S4A](#SD1){ref-type="supplementary-material"}). H3K36me3 is a broad histone mark that is enriched primarily in the body of the gene. To measure regions with enrichment of the mark, we used the SICER v1.1 package ([@R87]) that annotates ChIP signal over a stretch of DNA as "islands" (an island is defined as a cluster of non-overlapping consecutive DNA regions (200-bp windows) separated by at least a 600-bpgap region of DNA with no ChIP-enriched signal detected above threshold). Annotation of the H3K36me3 islands shows that they were primarily present within the gene body compared to promoter proximal regions, as expected ([@R46]; [@R79]) ([Figure 6B](#F6){ref-type="fig"}). Metagene analysis showed there to be no genotype-specific difference in the distribution of marks overall along the gene body and no effect of gene length ([Figures S4B](#SD1){ref-type="supplementary-material"}--S4D). We further compared the differential enrichment of the H3K36me3 islands within the replicates by a negative binomial test performed using edgeR ([@R68]) (fold change \>2 and p \< 0.05). We found 363 islands with decreased and 2,223 islands with increased H3K36me3 in the *Fmr1*KO compared to WT hippocampus ChIP-seq in both replicates ([Table S2](#SD3){ref-type="supplementary-material"}). Examples of the changes of these marks that are genotype-dependent are shown in [Figure 6C](#F6){ref-type="fig"} where H3K36me3 on *Reep4* (receptor expression-enhancing protein 4) is reduced but elevated on *Tprkb* (TP53-related protein kinase-binding protein). The decreased islands were fewer and mostly found in intragenic regions, whereas the increased islands were enriched and present in both the intragenic and intergenic regions ([Figure 6D](#F6){ref-type="fig"}), demonstrating a redistribution of H3K36me3 in FXS model mice. Many of the islands, especially those that increase in *Fmr1* KO animals, are found on genes linked to autism spectrum disorders as defined by Simons Foundation Autism Research Initiative (SFARI) ([Figure 6E](#F6){ref-type="fig"}). A subset of genes (37) showed both increased and decreased islands, but at different locations on the gene body ([Figure 6E](#F6){ref-type="fig"}). GO term enrichment analysis of the genes that increased H3K36me3 islands is shown in [Figure 6F](#F6){ref-type="fig"}. The genes with increased H3K36me3 islands are remarkably enriched for those involved in neural function such as synapse assembly and animal behavior. No significant GO terms were enriched in the group of genes with decreased H3K36me3 islands. We find no correlation between steady-state RNA abundance and H3K36me3 levels on islands in the genes ([Figure S4F](#SD1){ref-type="supplementary-material"}), which could be attributed to compensatory post-transcriptional mechanisms affecting steady-state RNA. Furthermore, the methylated islands also undergo genotype-specific length changes; they are significantly longer in the WT compared to *Fmr1* KO (p \< 0.001, Kolmogorov-Smirnov \[K-S\] test) ([Figure S4E](#SD1){ref-type="supplementary-material"}). Our data thus show that an increase in the levels of SETD2 in the *Fmr1* KO resulting primarily in increased H3K36me3 chromatin marks at a subset of genes.

FMRP Regulates Alternative RNA Processing {#S6}
-----------------------------------------

H3K36me3 in mammals has been correlated with alternative pre-mRNA splicing ([@R41]). We analyzed our RNA-seq data from WT and *Fmr1* KO hippocampal slices using the rMATS alternative splicing package ([@R73]) and detected many alternative pre-mRNA processing events including skipped exon (SE), mutually excluded exon (MXE), and alternative 5′ and 3′ splice site (A5SS and A3SS) ([Figure 7A](#F7){ref-type="fig"}; [Table S3](#SD4){ref-type="supplementary-material"}; FDR \< 5% and p \< 0.05). The number of exon inclusion events are shown (differences in exon inclusion levels is calculated as percent spliced in \[PSI\], and a cutoff of \|deltaPSI\| ≥5% is used). Several of the exon-skipping events were validated by qRT-PCR, with \~20%--40% reduction in exon skipping in the *Fmr1* KO relative to WT ([Figure 7B](#F7){ref-type="fig"}). These skipped exons have previously been found to be associated with defects in brain development and disease pathology ([@R1]; [@R19]; [@R69]; [@R83]). In particular, an increase in microexon 4 skipping in *Cpeb4* mRNA was found in postmortem cortical tissue from autism patients. Consequently, a mouse model of *Cpeb4* microexon 4 deletion recapitulated the molecular and behavioral phenotypes found in autism patients ([@R36]; [@R62]; [@R63]). [Figure 7C](#F7){ref-type="fig"} shows all the RNA processing events that undergo changes in *Fmr1*-deficient hippocampus relative to WT (p \< 0.05, \|deltaPSI\| ≥5%). Skipped exons are by far the most prevalent category, followed by alternative 3′ splice sites. The genes whose RNA processing events are altered in *Fmr1* KO are strongly linked to neural function such as vesicle transport to synapses and vesicle recycling ([Figure 7D](#F7){ref-type="fig"}). Moreover, many of the genes with alternative splicing events (Alt. Spl.) in *Fmr1* KO hippocampus (Alt. Spl. *Fmr1* KO) are linked to autism (i.e., SFARI autism spectrum disorder database \[ASD\]) ([Figure 7E](#F7){ref-type="fig"}). In addition, the Alt. Spl. genes in *Fmr1* KO significantly overlap with genes previously found to display alternative splicing in patients with autism (Alt. Spl. ASD) ([@R60]) ([Figure 7E](#F7){ref-type="fig"}). We also find an overlap of genes with changes in H3K36me3 islands with those found to harbor aberrant splicing in *Fmr1* KO tissue ([Figure 7E](#F7){ref-type="fig"}). We found no correlation between amount of exon skipping and RNA abundance, RPF levels or presence of FMRP CLIP tags at the gene level ([Figures S5A](#SD1){ref-type="supplementary-material"}--[S5C](#SD1){ref-type="supplementary-material"}). We next assessed the H3K36me3 levels at the skipped exons in the SE category and found a significant decrease in the H3K36me3 marks at the 5′ splice site (±50 nt) of these exons that are skipped in the *Fmr1* KO hippocampus compared to the WT ([Figure 7F](#F7){ref-type="fig"}; p = 0.02 using the Wilcoxon test). Interestingly, when we increased the analysis over a region of ± 150 nt (\~2 nucleosomes) we no longer found a decrease in H3K36me3 at the skipped exons in the FMRP KO animal ([Figure S5D](#SD1){ref-type="supplementary-material"}). Although at the island level, which encompasses mainly regions \>1 kb, we see mainly an increase in H3K36me3 levels, but at the 5′ splice site of genes (±50 nt) susceptible to alternative splicing in the FMRP KO, we see a decrease in H3K36me3 levels. Further studies are needed to understand how H3K36me3 modifications and/or other factors might play a role in regulating differential alternative splicing in the FMRP KO background. Thus, as with other autism spectrum disorders, dysregulated alternative splicing is prevalent in a mouse model of FXS and might be linked to changes in H3K36me3 levels at the splice site.

DISCUSSION {#S7}
==========

We used several approaches to investigate FMRP regulation of mRNA expression in the mouse brain, focusing first on steady state ribosome profiling in hippocampal slices. *Fmr1* deficiency resulted in ribosome footprint levels that mostly tracked altered levels of RNA, which is consistent with other studies ([@R50], [@R51]; [@R11]). Because ribosome profiling at steady state cannot distinguish between static and translocating ribosomes, we modified our profiling procedure ([@R35]) to identify the dynamic range of ribosome translocation rates genome-wide in hippocampal slices. These studies in turn resulted in four main findings. First, they showed that mRNAs cluster into defined functional biology groups based on the transit rates of their associated ribosomes. The ribosomes on most mRNAs (\>5,000) transit rapidly, whereas on some mRNAs (\~3,000), ribosome transit is slow or nearly not at all (\~350). There is some CDS length dependency as well. Second, using a combination of ribosome runoff and sucrose gradient centrifugation, we identified \~50 mRNAs associated with FMRP-stalled ribosomes, which strongly imply translational regulation. One of these mRNAs encodes a histone lysine methyltransferase, SETD2, which is elevated in *Fmr1* KO hippocampus. Third, the SETD2-dependent histone mark, H3K36me3, is rearranged in both intragenic and intergenic regions upon *Fmr1* deficiency; primarily increases in H3K36me3 are observed in *Fmr1* KO. Fourth, because H3K36me3 has been correlated with alternative RNA processing in mammals ([@R41]), we analyzed our RNA-seq data and found widespread aberrant splicing in the *Fmr1* KO hippocampus, most prominently exon skipping/inclusion. These altered processing events often correlated with changes in the histone mark, occurred on genes that regulate pre-synaptic functions, such as synaptic vesicle recycling, and were strongly linked to autism spectrum disorders ([Figure 7E](#F7){ref-type="fig"}).

Earlier studies have inferred that ribosome stalling in the brain is linked to RNA transport granules in dendrites ([@R45]; [@R54]; [@R38]; [@R40]; [@R22]). It is possible that at least some of the ribosome stalling we observe may be the result from such compartmentalization in neurons or perhaps is a more general feature of the brain. In contrast, rapidly dividing ES cells do not appear to have stalled ribosomes, at least not of the magnitude we observe here ([@R35]). Irrespective of whether ribosome stalling is a dendritic or neuronal phenomenon, how it occurs mechanistically on specific mRNAs is unclear, but it could be related to secondary structure or association with RNA binding or other proteins. One clue, however, could be the accumulating evidence that strongly implicates phosphorylation of eEF2 as a coordinator of translation and neural activity and thus is likely to be one mediator of ribosome translocation rates ([@R71]; [@R76]; [@R61]; [@R56]; [@R27]). Even so, the involvement of phospho-eEF2, a general translation factor, would unlikely be responsible for mRNA-specific stalling. We also noted that some mRNAs, such as those in subcluster 2 ([Figures 3D](#F3){ref-type="fig"} and [3E](#F3){ref-type="fig"}), encode proteins involved in the extracellular matrix ([Figure S2C](#SD1){ref-type="supplementary-material"}). A number of these proteins contain proline-rich stretches, whose geometry in the polypeptide exit tunnel can lead to ribosome stalling ([@R72]; [@R32]).

We have identified 48 mRNAs whose ribosomes are stalled specifically by FMRP. These RNAs include those with (40 mRNAs) and without FMRP CLIP (8 mRNAs) sites in coding regions ([@R10]; [@R82]), so it would appear that a simple FMRP "roadblock" model would not explain ribosome stalling. Alternatively, [@R37] showed that *Drosophila* FMRP binds ribosomal proteins, and in a cryoelectron microscopy (cryo-EM) study, [@R7] found that *Drosophila* FMRP reconstituted with mammalian ribosomes binds a region that would preclude tRNA and elongation factors from engaging in translation. However attractive this model is for FMRP-mediated ribosome stalling, the fact that mRNA or translation factors were not included in the reconstitution assays brings into question whether it reflects the physiological basis for ribosome stalling.

Our studies revealed that FMRP stalls ribosomes on a number of mRNAs that encode epigenetic regulators and that the misregulation of one of them in *Fmr1*-deficient hippocampus, SETD2, leads to a widespread increase in H3K36me3 chromatin marks (islands). These H3K36me3 islands are both enriched for and depleted from autism-risk genes ([Figure 6E](#F6){ref-type="fig"}) as well as those with synaptic functions ([Figure 6F](#F6){ref-type="fig"}). This suggests that SETD2, the main enzyme that catalyzes this chromatin mark, might also be an autism-risk gene, which has been previously reported ([@R52]). Mutations in several chromatin-remodeling genes have been linked to changes in neural function, autism, and other intellectual disabilities ([@R81]; [@R21]). In most cases, however, mutations in epigenetic modifiers result in up or downregulation of transcription. Indeed, previously identified epigenetic changes in FXS model mice by [@R44], particularly H3K4me3, H4K8ac, and H4K16ac, were responsible for widespread changes in transcription in cortical neurons and the cerebellum. Importantly, these investigators could rescue several FXS pathophysiologies, many of which resemble those in autism, by targeting the epigenetic reader protein Brd4. H3K36me3 does not mark promoter regions but instead is found in gene bodies and increases as RNA polymerase II proceeds 3′ during catalysis ([@R57]). In mammals, one of the functions H3K36me3 is correlated with, if not causative for, is alternative pre-mRNA processing ([@R41]). In the *Fmr1*-deficient hippocampus, we detected extensive changes in RNA processing, mostly exon skipping. Surprisingly, most of the skipped exons occurred in genes that have pre-synaptic functions such as synaptic vesicle recycling, transport, and exocytosis, which could at least partially explain alterations in synaptic vesicle dynamics and neurotransmitter release in FXS model mice ([@R12]; [@R17]; [@R6]). Furthermore, a number of skipped exons in *Fmr1* KO have been linked to neurological disorders such as autism (skipped microexon 4 in *Cpeb4*; [@R36]; [@R62]; [@R63]), Alzheimer's disease (skipped exon 7 in *APP*; [@R18]; [@R69]), Parkinson's disease (skipped exon 3 in *Mapt*; [@R47]; [@R86]), and intellectual disabilities (skipped exon 12 in *Cnksr2*; [@R29]).

Alternative pre-mRNA processing is a common feature in autism ([@R65]; [@R64]), so it is perhaps not surprising that this would occur in fragile X. However, because FMRP is an RNA-binding protein that regulates translation, a reasonable assumption would be that mRNAs encoding splicing factors are improperly expressed in the disorder and that this leads directly to mis-splicing events. However, our data indicate that this relationship might not be linear. Instead, we find that FMRP controls ribosome dynamics on specific mRNAs, which leads to elevated translation (e.g., SETD2), which leads to chromatin modifications (e.g., H3K36me3), which in turn might lead to alternative splicing of neuronal mRNAs ([Figure 7G](#F7){ref-type="fig"}). These observations do not preclude the possible, if not likely, direct involvement of FMRP in some of these events. Even so, inferences that fragile X is a disorder of improper translation, while not incorrect, are vastly over-simplified. However, the complexity of gene expression changes in fragile X might offer opportunities for therapeutic intervention at multiple steps.

STAR★METHODS {#S8}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S9}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Joel Richter (<joel.richter@umassmed.edu>). This study did not generate new unique reagents.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S10}
--------------------------------------

All experiments were approved by the Institutional Animal Care and Use Committee at University of Texas Southwestern and University of Massachusetts Medical School and conducted in accordance with the National Institutes of Health Principles of Laboratory Animal Care. *Fmr1* KO mice were obtained from Dr. Stephen T. Warren and backcrossed for more than 10 generations on a C57BL/6 background. Food and water were provided *ad libitum*, and mice were kept on a 12 h light/dark cycle (7am--7pm light period). Pups were kept with their dams until weaning at postnatal day 21. After weaning, mice were group housed (maximum of 5 per cage) by sex. Cages were maintained in ventilated racks in temperature (20--21°C) controlled rooms. P28--35 wild-type or *Fmr1* KO male mice littermates were used in this study.

### Cell culture {#S11}

Immortalized Mouse Embryonic Fibroblasts (MEFs) were derived from C57BL/6N wild-type or *Fmr1* KO mice as described earlier ([@R24]. Immortalized MEF cells were cultured in DMEM (Dulbecco's Modified Eagle's Medium, GIBCO) with 10% fetal bovine serum using the 3T3 culture protocol and cells derived from Passage number 31 onward were used for western blot analysis.

METHOD DETAILS {#S12}
--------------

### Mouse acute brain slice preparation {#S13}

Transverse hippocampal or hippocampal-cortical brain slices were acutely prepared from P28--35 C57BL/6N wild-type or *Fmr1* KO male mice littermates as previously described ([@R25]). Briefly, mice were anesthetized with ketamine (125 mg/kg)/xylazine (25 mg/kg) and transcardially perfused with chilled (4°C) sucrose dissection buffer containing the following (in mM): 2.6 KCl, 1.25 NaH~2~PO~4~, 26 NaHCO~3~, 0.5 CaCl~2~, 5 MgCl~2~, 212 mM sucrose, and 10 dextrose aerated with 95% O~2~/5% CO~2~. Transverse hippocampal slices (400μm) were obtained on a Leica VT1200S slicer. For ribosomal profiling experiments ([Figure 1](#F1){ref-type="fig"}), CA3 was cut off to enrich for CA1 and for each biological replicate (n), 8--10 slices from 6--8 mice/genotype were pooled. Slices were recovered and maintained at 30°C for 3--4 h in artificial cerebrospinal fluid (ACSF) which contained the following (in mM): 119 NaCl, 2.5 KCl, 2 CaCl~2~, 1 MgCl~2~, 26 NaHCO~3~, 1 NaH~2~PO~4~ and 11 D-glucose aerated with 95%/O~2~/5% CO~2~ to pH 7.4. Slices were then treated with cycloheximide (100 μg/ml) in ACSF, 4°C, snap-frozen on dry ice/EtOH bath, and stored at 80°C. For homoharringtonine (HHT) experiments ([Figures 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}, and [5](#F5){ref-type="fig"}), cortical-hippocampal slices were recovered 3--4 hours in ACSF and then treated with HHT (20 μM) (Tocris) or 0.05% DMSO (vehicle) for different times (0, 5, 10, 30, 60 min). At the end of the incubation time, slices were snap/frozen on dry ice/EtOH bath and stored at −80 C. Ten slices from 2--3 mice/genotype were pooled for each biological replicate.

### Sucrose gradients of hippocampal slices for steady-state ribosome profiling {#S14}

Frozen, isolated CA1 hippocampal slices were thawed in ice-cold homogenization buffer (20mM Tris-HCl pH7.4, 5mM MgCl~2~, 100mM KCl, 1mM DTT, 100 μg/ml CHX (cycloheximide), 25U/ml Turbo DNaseI (Ambion, \#AM2238), 1X EDTA-free protease inhibitor (Roche), avoiding detergent in nuclease-free water) on ice for 5min. Wide orifice tips were used to transfer slices to a pre-chilled detergent-free Dounce homogenizer. Tissues were slowly homogenized by hand (20 strokes of loose pestle A, and 20 strokes of tight pestle B). Homogenates were carefully transferred to clean 1.5ml tubes with clean glass Pasteur pipets and bulbs. 1% NP-40 was added to the homogenates and incubated on ice for 10min. Homogenates were clarified by centrifugation at 2,000 g 4°C for 10min. The supernatants were collected and clarified again by centrifugation at 20,000 g 4°C for 10min. The supernatants were collected, and the amounts of nucleic acid were measured by Nanodrop (A~260~ units). For each sample, cytoplasmic RNA for RNA-seq was purified from one-fourth of the lysate with TRIzol LS reagent (Invitrogen, \#10296028). The other three-fourths of the lysate was digested with 100ng RNase A (Sigma, \# R4875) and 60U RNase T1 (Thermo Fisher Scientific, \#EN0542) per A~260~ at 25°C for 30 min and stopped by chilling on ice and adding 50U SUPERase In RNase inhibitor (Ambion, \#AM2694). Digested lysates were applied to 10%--50% (w/v) sucrose gradients prepared in 1X polysome buffer (20mM Tris-HCl pH7.4, 5mM MgCl~2~, 100mM KCl, 1mM DTT, 100 μg/ml CHX in nuclease-free water). After the ultracentrifugation in a SW41Ti rotor (Beckman Coulter) at 35,000 rpm (avg 151,263 g) 4°C for 2.5 h, gradients were fractionated at 1.5 ml/min and 12 s collection intervals through a fractionation system (Brandel) that continually monitored A~260~ values. Monosome fractions were identified, pooled, and extracted with TRIzol LS.

### Sucrose gradients of cortical-hippocampal slices for run-off ribosome profiling {#S15}

Frozen cortical-hippocampal slices were thawed in ice-cold lysis buffer (20mM Tris-HCl pH7.4, 5mM MgCl~2~, 100mM KCl, 1mM DTT, 100 μg/ml CHX, 25U/ml Turbo DNaseI, 1X EDTA-free protease inhibitor, 1% NP-40, in nuclease-free water) on ice for 5min. Tissues were dissociated by pipetting and further trituration through 25G needle for 10 times. Lysates were incubated on ice for 10min and then clarified by centrifugation at 2,000 g 4°C for 10min. The supernatants were collected and clarified again by centrifugation at 20,000 g 4°C for 10min. The supernatants were collected, and the amounts of nucleic acid were measured with Qubit HS RNA assays. Lysates containing \~40μg RNA were digested with 600ng RNase A (Ambion, \#AM2270) + 75U RNase T1 (Thermo Fisher Scientific, \#EN0542)/μg RNA in 0.3ml at 25°C for 30min and stopped by chilling on ice and adding 50U SUPERase In RNase inhibitor. Digested lysates were applied to 10%--50% (w/v) sucrose gradients similarly as above.

### Sucrose gradients of cortical-hippocampal slices for polysome profiling {#S16}

Frozen cortical-hippocampal slices were thawed in ice-cold homogenization buffer on ice for 5min. Wide orifice tips were used to transfer slices to a pre-chilled detergent-free Dounce homogenizer. Tissues were gently homogenized by hand (3 strokes of loose pestle A, and 7 strokes of tight pestle B). Homogenates were carefully transferred to clean 1.5ml tubes with clean glass Pasteur pipets and bulbs. Homogenates were clarified by centrifugation at 2,000 g 4°C for 10min. The supernatants were collected and clarified again by centrifugation at 10,000 g 4°C for 10min. The supernatants were collected, and the amounts of nucleic acid were measured with Nanodrop (A~260~ units). 1% NP-40 was added to the homogenates and incubated on ice for 10min. \~1A~260~ unit of lysate was saved for the input RNA. \~5 A~260~ units of lysate were applied to 15%--45% (w/w) sucrose gradients prepared in 1X polysome buffer and with the lower block mark and long cap. After the ultracentrifugation in a SW41Ti rotor (Beckman Coulter) at 35,000 rpm (avg 151,263 g) 4°C for 2 h, gradients were fractionated at 1.5 ml/min and 20 s collection intervals through a fractionation system (Brandel) that continually monitored A~260~ values. Some gradients were treated with RNase A prior to centrifugation.

### Ribosome profiling {#S17}

Ribosome profiling libraries were prepared following the published protocols ([@R28]). Briefly, rRNA was depleted from the purified monosomal RNA with RiboZero (Illumina, \#MRZG12324). Remaining RNA samples were separated on a 15% TBU gel (National Diagnostics, \#EC-833) and the ribosome footprints were size-selected between the 26 and 34nt markers. RNA was eluted from the crushed gel pieces in RNA elution buffer (300mM NaOAc pH5.5, 1mM EDTA, 0.25% SDS) at room temperature overnight, filtered with Spin-X Centrifuge Tube Filters (Corning, \#8162) and precipitated with equal volume of isopropanol. Recovered RNA was dephosphorylated with T4 Polynucleotide Kinase (NEB, \#M0201S) and ligated with preadenylated adaptor in miRCat®−33 Conversion Oligos Pack (IDT) using T4RNL2Tr.K227Q ligase (NEB, \#M0351L). Reverse transcription (RT) was performed with primers containing 5nt-barcodes and 8nt-unique molecular identifiers (UMIs) and SuperScript III (Invitrogen, \#18080--044) in 1X first-strand buffer without MgCl~2~ (50 mM Tris-HCl, pH 8.3, 75 mM KCl). RT products were separated on a 10% TBU gel and the 130--140nt region was selected. cDNA was eluted in DNA elution buffer (10mM Tris pH 8.0, 300mM NaCl, 1mM EDTA) at room temperature overnight, filtered, and precipitated with isopropanol. Purified cDNA was circularized with CircLigase (Epicenter, \#CL4115K). Except for the RNase titration samples, cDNA derived from remaining rRNA was hybridized to biotin-labeled antisense probes (IDT) and further depleted with Dynabeads MyOne Streptavidin C1 (Invitrogen, \#65001). Optimal PCR cycle number was determined empirically by test PCR reactions with titrated cycle numbers. Final PCR amplification was performed with KAPA Library Amplification Kit (Kapa Biosystems, \#KK2611) and 180--190bp products were size-selected on an 8% TBE gel. DNA was eluted in DNA elution buffer, filtered, and precipitated with isopropanol. The final library DNA was purified with AMPure XP beads (Beckman Coulter, \#A63880). Oligos used for the library preparation are listed in [Table S2](#SD3){ref-type="supplementary-material"}.

In parallel, input RNA samples were processed similarly as the ribosome footprints except the following steps. After rRNA depletion, input RNA mixed with an equal volume of 2x alkaline fragmentation solution (2 mM EDTA, 10 mM Na~2~CO~3~, 90 mM NaHCO3, pH \~9.3) and heated at 95°C for 15min to achieve an average fragment length of \~140nt. Fragmented RNA samples were separated on a 10% TBU gel and size-selected between the 100 and 150nt markers. RT products were separated on a 10% TBU gel and the 200--250nt region was selected. Antisense probe depletion was omitted for input RNA samples. 260--300bp final PCR products were size-selected on an 8% TBE gel.

The size distributions of final libraries were measured by Fragment Analyzer (Advanced Analytical, performed by Molecular Biology Core Labs at UMMS). The concentrations were quantified with KAPA Library Quantification Kit (Kapa Biosystems, \#KK4835). Libraries were pooled with equal molar ratios, denatured, diluted, and sequenced with NextSeq 500/550 High Output Kit v2 (Illumina, 75bp single-end runs, \#FC-404--2005) on a Nextseq500 sequencer (Illumina).

### RNA-seq for polysome fractions {#S18}

Based on the FMRP signals in the immunoblotting of gradient fractions, medium and heavy fractions were identified, pooled, and extracted with TRIzol LS together with saved input lysates. RNA samples were quantified with Qubit HS RNA assay kit and the integrity was examined with Fragment Analyzer. 200ng RNA was used for BIOO Rapid directional qRNA-seq library preparation following the manufacturer's instructions. 12 cycles were used for the final PCR amplification. The libraries were quantified with KAPA Library Quantification Kit and the quality was examined with Fragment Analyzer. Libraries were pooled with equal molar ratios, denatured, diluted, and sequenced with NextSeq 500/550 High Output Kit v2 (Illumina, 80bp pair-end runs for RNA-seq, \#FC-404--2002) on a Nextseq500 sequencer (Illumina).

### Western blotting {#S19}

Hippocampi were homogenized at 4°C in RIPA buffer. Protein complexes were released by sonication at 4°C and the extract was centrifuged at 13,200 rpm for 10 min at 4°C and the supernatant collected. Protein concentration was determined by BCA reagent. Proteins (10 μg) were diluted in SDS-bromophenol blue reducing buffer with 40 mM DTT and analyzed using western blotting with the following antibodies: SETD2 (ABclonal, A11271) and Lamin AC (Thermo Fisher, 14-9688-80). After incubation in primary antibody, immunoblots were incubated with HRP-conjugated secondary antibodies (Jackson Immunoresearch) and developed by Clarity ECL substrate (Biorad). For western blots for SETD2 detection, Hippocampi or MEF cells were homogenized in Triton Extraction Buffer (TEB: PBS containing 0.5% Triton X 100 (v/v), 2 mM phenylmethylsulfonyl fluoride (PMSF), 0.02% (w/v) NaN~3~), centrifuged at 2000 rpm. The pellet containing the nuclei was resuspended in RIPA Buffer and Protein complexes were released by sonication at 4°C. Protein concentration was determined by BCA reagent. Proteins (30 μg) were diluted in SDS-bromophenol blue reducing buffer with 40 mM DTT and analyzed using western blotting with the following antibodies: SETD2 (ABclonal, A11271) and Lamin AC (Thermo Fisher, 14-9688-80) or Lamin B1 (Abcam, ab16048). After incubation in primary antibody, immunoblots were incubated with HRP-25 conjugated secondary antibodies (Jackson Immunoresearch) and developed by Clarity ECL. For sucrose gradient fractions, 60μl samples were mixed with 20μl 4X SDS loading dye (240mM Tris-HCl pH 6.8, 5% beta-mercaptoethanol, 8% SDS, 40% glycerol, 0.04% bromophenol blue) and boiled at 95°C for 10min. Samples were briefly heated at 95°C again for 30sec immediately before loading on 10% SDS-PAGE gel (35 ml/sample). Separated proteins were transferred to PVDF membranes at constant 90 mA 4°C for 16 h. Membranes were blocked with 5% non-fat milk in 1X TBST at room temperature for 1hour and incubated with primary antibody at 4°C overnight. FMRP (Abcam, 1: 2000), Tubulin (Sigma, 1:5000), Rpl4 (Proteintech, 1:5000), UPF1 (Abcam, 1: 5000), MAP2 (Millipore, 1:2000), eEF2 (Cell signaling, 1:2000), GAPDH (Cell signaling, 1:2000), MRPS18B (Proteintech, 1:2000) and Rps6 (Cell signaling, 1:4000) were diluted in 1X TBST with 5% non-fat milk. Membranes were washed three times for 10min with 1XTBST and incubated with anti-rabbit or anti-mouse secondary antibodies (Jackson, 1:10000) at room temperature for 1hour. Membranes were washed three times for 10min with 1XTBST, developed with ECL-Plus (Piece), and scanned with GE Amersham Imager

### Chromatin immunoprecipitation Sequencing (ChIP-Seq) {#S20}

ChIP was performed as previously described ([@R9]). Briefly, hippocampal tissue was isolated from 4 adult mice (P35) per genotype and minced into tissue \< 0.5mm^3^ in 250ul of ice-cold PBS with protease inhibitors. Tissue was cross-linked with 1% formaldehyde and rotated at room temperature for 15 min at 50 rpm and quenched with 150mm glycine for 10 min in a total volume of 1ml PBS. The supernatant was discarded after centrifugation at 2000 g for 10 min at 4°C and the pellet was resuspended in 300ul of chilled cell lysis buffer for 20 min on ice. Swollen pellets were homogenized using a glass Dounce homogenizer (2ml) with 40 strokes of a tight pestle on ice. Nuclei were harvested after centrifugation at 2000 g for 5min at 4°C and resuspended in 300ul ice-cold nuclear lysis buffer for 20min on ice. SDS was added to make a final concentration of 0.5%. Samples were sonicated on a Bioruptor® sonicator at high power settings for 9 cycles (sonication: 30 s on, 90 s off) of 15min each at 4°C at high power. Supernatants were collected after centrifugation at 16,000 g for 10 min at 4°C. The samples were diluted to bring the SDS concentration \< 0.1%; 10% of each sample was reserved as input. The rest of the samples were divided into two and incubated with Protein G dynabeads coupled overnight at 4°C with either H3K36me3 (Abcam ab9050, 5 mg per ChIP) or IgG (Sigma 12--371, 5 mg per ChIP). After IP, beads were washed, and chromatin eluted in elution buffer for 20 min shaking at 65°C. IP and Input samples were de-crosslinked overnight at 65°C. RNase digestion for 1 hr. at 37°C and proteinase K treatment for 30 min at 55°C was performed. DNA was then purified with the QIAGEN PCR purification kit in 50ul elution buffer. For library preparation, purified input and IP DNA was end repaired using T4 DNA polymerase, Klenow polymerase and T4 Polynucleotide kinase from NEB at 20°C for 30 min. DNA was extracted using 35ul of the Agencourt Ampure XP beads and 'A' bases were added to the 3^′^ end using Klenow exonuclease (3^′^ to 5^′^ exo minus) from NEB for 30min at 37°C. DNA was purified using 60ul of the Agencourt Ampure XP beads and Illumina adaptor sequences were ligated to the DNA fragments using the Quick Ligase (NEB) for 15min at 20°C. The library was size-selected using 50ul of Agencourt Ampure XP beads. Using the multiplexing barcoded primers, the library was PCR amplified and purified using 50ul of the Agencourt Ampure XP beads and analyzed using a Fragment Analyzer (Advanced Analytical, performed by Molecular Biology Core Labs at UMMS). Libraries were pooled with equal molar ratios, denatured, diluted, and sequenced with NextSeq 500/550 High Output Kit v2.5 (Illumina, 75bp paired-end runs,) on a Nextseq500 sequencer (Illumina).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S21}
---------------------------------------

All grouped data are presented as mean ± s.e.m. All tests used to compare the samples are mentioned in the respective figure legends and corresponding text. When exact p values are not indicated, they are represented as follows: \*, p \< 0.05; \*\*, p \< 0.01; \*\*\*, p \< 0.001; \*\*\*\*, p value \< 0.0001; n.s., p \> 0.05.

### Ribosome profiling analysis {#S22}

Individual samples were separated from the raw fastq files based on the barcode sequences. Adaptor sequences (TGGAATTCTCGGGTGCCAAGGAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAGACCG) were removed with cutadapt (1.7.1). Trimmed fastq files were uploaded to the Dolphin platform (<https://www.umassmed.edu/biocore/introducing-dolphin/>) at the UMMS Bioinformatics Core for the mapping steps. Trimmed reads were quality filtered with Trimmomatic (0.32) and mapped to the mouse rRNA and then tRNA references with Bowtie2 (2.1.0). Unmapped reads were next mapped to the mm10 mouse genome with Tophat2 (2.0.9). Reads mapped to \> 1 loci of the genome were classified as "multimapped" reads and discarded. PCR duplicates were marked based on the UMI sequences with custom scripts and only uniquely mapped reads without duplicates were retained with Samtools (0.0.19) for the downstream analyses. RPF length distribution, P-site offsets, and frame preference were calculated with plastid (0.4.8). Counts at each nucleotide position were extracted using P-sites of RPFs and 5^′^ end of mRNA reads with +11 offset, normalized to the library size, averaged across replicates, and plotted along mRNA positions with custom scripts.

### Steady-state differential translation analysis {#S23}

Cleaned bam files were converted to fastq files with bedtools. For both ribosome profiling and RNA-seq, gene expression was quantified with RSEM (1.2.11) using the cleaned fastq files and Refseq (V69) mouse CDS without the first and last 30nt to avoid the translation initiation and termination peaks. Genes were filtered with minimum 10 reads across all replicates and then the read counts were batch-corrected with the Combat function in sva (3.24.4) using a full model matrix. Batch-corrected counts were normalized with trimmed mean of M values (TMM) method and used to identify differential expressed genes (DEGs) with anota2seq (1.0.0). Instead of the default setting, the priority of TE groups were set to be higher than that of mRNA only groups. A permutation test was performed to estimate the false discovery rate (FDR) with nominal p value \< 0.01, which was 0.097. GO analysis was performed and plotted with clusterProfiler (3.10.1; [@R88]) using all genes past filtering in the dataset as the background.

### Hierarchical clustering of ribosome run-off and gene ontology (GO) enrichment of each cluster {#S24}

RPFs were mapped as described above and the most abundant isoform estimated by RSEM for each gene was selected as the representative transcript. For the metagene analysis, transcripts with CDS longer than 3000nt (n = 1401) were selected to ensure incomplete ribosome run-off after 10min HTT treatment. The read densities at each nucleotide position were normalized to the average density of the last 500nt of CDS and averaged using the P sites of RPFs. For visualization purposes, the curves were smoothed within a 90nt window. An arbitrary 0.8 threshold was used to estimate the relative run-off distances at 5 and 10min. A linear regression analysis between the HHT treatment time and ribosome run-off distances was performed to estimate the global elongation rate. To visualize the run-off patterns for individual transcripts, RPFs were normalized to the abundance of mitochondrial RPFs and plotted along the mRNA nucleotide positions. The same y-scale was used across the time-course, so the initiation peaks were truncated to reveal the patterns over CDS. Stalled ribosomes were quantified by RSEM by mapping RPFs to Refseq (V69) mouse CDS without the first and last 300nt to avoid the translation initiation and termination peaks after prolonged HTT treatment. Counts of RPFs were normalized to the length of CDS minus 600nt and the abundance of mitochondrial RPFs in that sample to calculate the RPK (Reads Per Kilobase of transcript) value for each transcript.

To categorize and group genes with distinct ribosome run-off patterns, the RPF of each gene at each time point was first normalized to time point 0. The Euclidean distance matrix was then calculated, followed by hierarchical clustering using Ward's agglomeration method ([@R84]). The clustering process was performed using the hclust ([@R20]), and the clustering heatmap was displayed using pheatmap ([@R43]) in R. To test the reliability of clustering, analysis of group similarities (ANOSIM) test ([@R8]) was performed using vegan ([@R13]) in R with 1000 permutation times on both overall clusters and sub-clusters. The global pattern of each cluster was summarized using the corresponding median and standard deviation in each time point.

GO enrichment analysis for each sub-cluster were performed through clusterProfiler ([@R88]) using genes covered by run-off ribosome profiling as background. The statistical significance was adjusted using FDR. To remove redundancy in reporting, each reported GO term was required to have at least 25% of genes that were not associated to another term with a more significant p value.

### Polysome fraction RNA-seq data analysis {#S25}

Fastq files were uploaded to the Dolphin platform at the UMMS Bioinformatics Core for mapping and quantification. 9nt molecular labels were trimmed from both 5^′^ ends of the pair-end reads and quality-filtered with Trimmomatic (0.32). Reads mapped to mouse rRNA by Bowtie2 (2.1.0) were filtered out. Cleaned reads were next mapped to the Refseq (V69) mouse transcriptome and quantified by RSEM (1.2.11).

Estimated counts on each gene were used for the differential gene expression analysis by DESeq2 (1.16.1). After the normalization by median of ratios method, only the genes with minimal 5 counts average across all samples were kept for the DEG analysis. Data were fit to a model of treatment+fraction+treatment:fraction+treatment:genotype:fraction and the treatmenthht.fractionheavy result was used to identify mRNA enriched or depleted in the heavy fractions after HTT treatment. p \< 0.05 and 2-fold change were used as the cut-offs.

For the medium fractions after HHT treatment, *Fmr1* KO samples was directly compared to the WT samples and p \< 0.05 was used as the cut-off for identifying DEGs. Steady-state ribosome profiling data of the decreased DEGs were compared to all the other genes to independently confirm whether these mRNAs indeed had fewer stalled ribosomes in *Fmr1* KO.

### ChIP-Seq analysis {#S26}

For ChIP-sequencing analysis, alignments were performed with Bowtie2 (2.1.0) using the mm10 genome, duplicates were removed with Picard and TDF files for IGV viewing were generated using a ChIP-seq pipeline from DolphinNext ([@R89]). The broad peaks for H3K36me3 ChIP-Seq were called using the SICER v1.1 package ([@R87]). H3K36me3 enriched islands were identified using the parameters set to a window size of 200bp, gap size 600bp and FDR cutoff of 1 × 10^−3^, and the default value for the redundant rate cutoff. To analyze the H3K36me3 difference level between WT and FMRP KO, the reads count on each island of each replicate was first normalized to total mapped reads and then normalized to its corresponding input sample. The H3K36me3 difference level of each island is then calculated using both replicates in FMRP KO and WT groups; a negative binomial test is performed using edgeR ([@R68]) to consider variability between replicates and differences between FMRP KO and WT groups. The islands with significantly different H3K36me3 levels are defined using a cut-off for fold change \>2 and p value \<0.05. Gene Ontology (GO) enrichment analysis was performed using the clusterProfiler package ([@R88]) to obtain GO terms related to Biological processes in the genes with differentially enriched islands in the *Fmr1* KO versus Wild-type. deepTools ([@R66]) was used to plot heatmaps and profiles for genic distribution of H3K36me3 ChIP signal. Samtools (0.1.19) was used for sorting and converting Bam files. RPGC (per bin) = number of reads per bin / scaling factor for 1× average coverage was used for normalization where the scaling factor was determined using sequencing depth: (total number of mapped reads × fragment length) / effective genome size. IGV tools (2.3.67) was used for visualizing TDF files and all tracks shown are normalized for total read coverage.

To quantify the H3K36me3 level at the 5^′^ and 3^′^ splicing sites of the SE, the read density at a region of ± 50nt at each splice site (total 100nt) and ± 150nt at each splice site (total 300nt) was normalized to the read density in the entire gene body, which controls for any fluctuations in total H3K36me3 at the respective genes between both genotypes (p value calculated using the Wilcox test for significance

### Alternative splicing analysis {#S27}

RNA-seq from hippocampal slices was used to analyze alternative splicing (AS) using the rMATS package v3.2.5 ([@R73]) with default parameters and reads were trimmed to 50bp. The Percent Spliced In (PSI) levels or the exon inclusion levels calculated by rMATS using a hierarchical framework. To calculate the difference in PSI between genotypes a likelihood-ratio test was used. AS events with an FDR \< 5% and \|deltaPSI\| ≥ 5% as identified using rMATS were used for further analysis. We included genes that had at least one read at the differential splice junction for both genotypes. GO enrichment analysis was done by the clusterProfiler package ([@R88]) to obtain GO term enrichment for the AS events. The genes with significant skipped exons were used for validation using RT-qPCR analysis. One ug of RNA from hippocampal tissue was used to generate cDNA using the Quantitech two-tep cDNA synthesis kit. Primers were designed to overlap skipped/inclusion exon junctions and qPCR was performed using the Bio-Rad SYBR reagent on a Quantstudio3 instrument.

DATA AND CODE AVAILABILITY {#S28}
--------------------------

Codes and scripts used for quantification analysis were written in Python or R and will be provided upon request to the Lead Contact.. The Gene Expression Omnibus (GEO) accession number for the data reported in this paper is GSE143333.
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![Ribosome Profiling Reveals Diverse Changes of Gene Expression in Fmr1 KO Hippocampus\
(A) Schematic diagram of the hippocampal slice preparation. To reduce spontaneous electrical activity, region CA3 was excised. 8--10 slices from six to eight mice/genotype were pooled per biological replicate (wild-type \[WT\], n = 4 and *Fmr1* KO, n = 3).\
(B) Schematic diagram of the experimental procedures for ribosome profiling.\
(C) Scatterplot of expression changes of mRNA levels and ribosome-protected fragments (RPFs). Dysregulated mRNAs in the absence of FMRP are classified into four regulatory groups. 14,459 genes past filtering are used for the scatterplot. Nominal p \< 0.01, FDR = 0.097 by permutation test. FC, fold change; TE, translational efficiency.\
(D) Top three GO terms of Biological Process enriched in each regulatory group. The enrichment (gene ratio) is represented by the size of dots. The enrichment significance (adjusted p value) is colorcoded.\
(E) Top three GO terms of Cellular Component enriched in each regulatory group.\
See also [Figure S1](#SD1){ref-type="supplementary-material"} and [Table S1](#SD2){ref-type="supplementary-material"}.](nihms-1581010-f0002){#F1}

![Characterization of Genes with TE Changes in Fmr1 KO Hippocampus\
(A) Heatmap of expression changes (log~2~FC KO/WT) for the top 20 RNAs in the "TE up" group.\
(B) Heatmap of expression changes (log~2~FC KO/WT) for the top 20 RNAs in the "TE down" group.\
(C) Read distributions on the *Gfpt2* RNA of TE-up group. Normalized RPF reads (top) and mRNA reads (bottom) averaged across all replicates are plotted along the mRNA nucleotide positions with green and red triangles for annotated start and stop codons, respectively. For visualization purposes, the curves were smoothed within a 30-nt window.\
(D) Read distributions on the *Lhfpl2* RNA of the TE-down group.\
(E) Boxplots visualize the medians of expression changes for FMRP CLIP targets. The lower and upper hinges correspond to the first and third quartiles. The whiskers extend from the hinges to the largest and smallest values no further than 1.5-fold of interquartile range. Outliers are not shown. Gene expression changes of CLIP genes were compared to those of all genes used for differential expressed genes (DEG) analysis (ns, not significant; \*\*\*\*p \< 0.0001; Wilcoxon test). CLIP genes are the FMRP targets identified in ([@R10]). All grouped data are presented as mean ± s.e.m.\
(F) Overlap of the TE-down and TE-up genes detected in this study (orange) with those of [@R11] (green) and the TRAP-seq data of [@R78] (blue).\
(G) Schematic models of ribosome density (TE) changes that reflect increased protein synthesis rates.\
See also [Table S1](#SD2){ref-type="supplementary-material"}.](nihms-1581010-f0003){#F2}

![Runoff Ribosome Profiling of WT Mouse Brain Slices\
(A) Schematic diagram of homoharringtonine (HHT) runoff ribosome profiling. WT mouse brain slices were treated with 20 mM HHT, an inhibitor of translation initiation, to allow ribosome runoff for 5, 10, 30, and 60 min (t) at 30°C. 10 slices from two or three mice were pooled per time point of HHT treatment.\
(B) Metagene plot of RPFs after HHT treatment. Reads are mapped transcripts (n = 1,401) with CDS longer than 3,000 nt and aligned at the annotated start and stop codons (gray vertical dash lines). The read densities at each nucleotide position are normalized to the average density of the last 500 nt of CDS and averaged using the P sites of RPFs. For visualization purposes, the curves were smoothed within a 90-nt window. Black horizontal dash line indicates the arbitrary 0.8 threshold to estimate the relative runoff distances (black vertical dash lines).\
(C) Linear regression between the HHT treatment time and ribosome run-off distances (from B) to estimate the global elongation rate (4.2 nt/s).\
(D) Cluster analysis of gene groups with distinct ribosome runoff patterns. The RPFs of each gene at each time point was normalized to time 0. The Euclidean distance matrix was then calculated, followed by hierarchical clustering using Ward's agglomeration method ([@R84]).\
(E) Ribosome runoff patterns for each subcluster. The global pattern of each subcluster was summarized using the corresponding median and standard deviation in each time point. The number of RNAs in each subcluster is shown in parentheses.\
(F) Representative ribosome runoff profiles that reflect each subcluster. The runoff pattern for *Actin* is similar to subclusters 4--6.\
(G) Ribosome footprints for *Nrxn3* and *Actin* mRNAs during the runoff time period.\
(H) GO terms for subclusters 1 and 3. Gene ratio refers to the percentage of total differentially expressed genes in the given GO term.\
See also [Figure S2](#SD1){ref-type="supplementary-material"} and [Table S1](#SD2){ref-type="supplementary-material"}.](nihms-1581010-f0004){#F3}

![Substantial FMRP Remains Associated with Polysomes after HHT Treatment\
(A--D) WT mouse hippocampal slices were treated with DMSO vehicle (A) or 20 mM HHT (B) for 30 min at 30°C. In parallel, *Fmr1* KO mouse hippocampal slices were also treated with DMSO vehicle (C) or 20 mM HHT (D) for 30 min at 30°C. Slices were homogenized and applied to 15%--45% (w/w) sucrose gradients, which were fractionated with continuous monitoring of A~260~ after ultracentrifugation. Fractions were collected for immunoblotting with indicated antibodies to detect the association of FMRP with polysomes. 10 slices from two or three mice/genotype were pooled per biological replicate (WT, n = 2; *Fmr1* KO, n = 2).\
(E) RNA sedimenting to heavy fractions containing more than seven ribosomes from WT slices treated with HHT was analyzed relative to input. 1,574 RNAs were reduced and 686 were elevated relative to input after HHT treatment.\
(F) *Actin* mRNA reads in the designated conditions (WT; V, vehicle, I, input; H, heavy fractions; KO, *Fmr1* KO).\
(G) *Map 1b* mRNA reads in the designated conditions.\
(H) GO terms of RNAs depleted in heavy fractions relative to WT.\
(I) GO terms of RNAs enriched in heavy fractions relative to WT.\
See also [Figure S3](#SD1){ref-type="supplementary-material"} and [Table S1](#SD2){ref-type="supplementary-material"}.](nihms-1581010-f0005){#F4}

![FMRP Stalls Ribosomes on Specific mRNAs\
(A) RNA sedimenting to medium polysomes containing four to six ribosomes after HHT treatment of hippocampal slices; 46 RNAs are downregulated and 1 is upregulated in *Fmr1* KO relative to WT.\
(B) Downregulated RNAs in HHT-treated *Fmr1* KO slices primarily encode epigenetic and transcriptional regulators and proteins involved in neural function.\
(C) Example of *Ankrd12* RNA, which has reduced reads in *Fmr1* KO slices relative to WT after HHT (H) treatment. Input (I) reads are similar in both genotypes. M refers to medium fraction.\
(D) Boxplot showing the fold change of *Fmr*1 KO versus WT of all RNAs (white) compared to those identified in (A) and (B) (gray) with respect to steady-state RNA levels, RPFs, and TE (ns, not significant; \*\*p \< 0.01; \*\*\*p \< 0.001; Wilcoxon test). All grouped data are presented as mean ± s.e.m.\
(E) Western blot analysis of SETD2 and lamin AC in hippocampus from four WT and five *Fmr1* KO mice. When quantified and made relative to lamin AC, SETD2 was significantly increased in the KO (p = 0.0245, two-tailed t test). All grouped data are presented as mean ± s.e.m.\
See also [Table S1](#SD2){ref-type="supplementary-material"} and [Figure S5E](#SD1){ref-type="supplementary-material"}.](nihms-1581010-f0006){#F5}

![H3K36me3 Localization Is Altered in Fmr1 KO Hippocampus\
(A) Experimental design for *in vivo* ChIP-seq of H3K36me3 in hippocampus from adult WT (n = 4) and *Fmr1* KO (n = 4) mice.\
(B) Pie chart representing the genomic annotation of the total H3K36me3 islands identified in the WT and *Fmr1* KO ChIP-seq.\
(C) H3K36me3 ChIP-seq gene tracks for WT and *Fmr1* KO hippocampal tissue. The two sequencing tracks from each biological replicate (n = 2 \[pooled hippocampi from two mice/biological replicate\]) of WT and *Fmr1* KO were merged and overlaid. WT ChIP-seq tracks are in blue, and KO tracks are in green. The tracks for immunoprecipitation (IP) and input are displayed. The islands with significantly decreased (blue) or increased (green) tracks are shown below the RefSeq gene annotation (FDR \< 0.0001; p \< 0.01) as identified using the SICER package. *Reep4* shows decreased H3K36me3 islands in *Fmr1* KO, and *Tprkb* shows increased islands in *Fmr1* KO.\
(D) Distribution of significantly increased or decreased H3K36me3 islands in intragenic and intergenic regions of the genome using negative binomial test performed using edgeR ([@R68]) (fold change \>2 and p \<0.05). The total number of increased or decreased islands is indicated above the respective bars in the graph in *Fmr1* KO versus WT ChIP-seq.\
(E) Venn diagram for significant overlap of *Fmr1* KO misregulated H3K36me3 genes (increased islands in blue and decreased islands in green) with the ASD-linked genes from the SFARI database. A subset of genes showed both increased and decreased islands along the length of the gene body. The p value (hypergeometric test) is indicated next to the respective comparisons.\
(F) GO term enrichment of H3K36me3 differentially enriched genes in *Fmr1* KO versus WT (p adjust value \< 0.05). Gene ratio refers to the percentage of total differentially expressed genes in the given GO term.\
See also [Figure S4](#SD1){ref-type="supplementary-material"} and [Table S2](#SD3){ref-type="supplementary-material"}.](nihms-1581010-f0007){#F6}

![Global Analysis of FMRP-Mediated Alternative Splicing\
(A) Summary table of total splicing events in *Fmr1* KO and WT based on RNA-seq from hippocampal slices. Splicing events detected by rMATS at a FDR \<5% and a difference in the exon inclusion levels between the genotypes (deltaPSI) ≥5% are depicted.\
(B) Alternative splicing events validated using qRT-PCR are shown for several RNAs (hippocampus tissue, WT, n = 6; *Fmr1* KO, n = 6). The illustration depicts an example of exon skipping (green box) in the *Fmr1* KO. Primer positions are depicted with black bars. All grouped data are presented as mean ± s.e.m.\
(C) Alternative splicing events detected in *Fmr1* KO and WT hippocampus. Inclusion events that were significantly (p \< 0.05) increased (red), decreased (blue), or unchanged (gray) are indicated. The numbers of events in the up or down category are shown in red and blue, respectively. PSI, percent splice in/exon inclusion levels.\
(D) GO term enrichment for all alternative splicing events are shown (p adjust value \< 0.05). The total number of genes identified in the RNA-seq from ([Figure 1](#F1){ref-type="fig"}) was used as background. Gene ratio refers to the percentage of total differentially expressed genes in the given GO term.\
(E) Table depicting the overlap of the alternative splicing events (Alt. Spl.) in genes in this study with the SFARI autism spectrum disorder database, the Alt. Spl. genes identified in samples from autism patients ([@R60]), and genes with increased or decreased H3K36me3 islands from [Figure 6](#F6){ref-type="fig"}. The intensity of the color represents the increasing number of overlapping genes between the gene sets. Asterisks indicate statistical significance (\*p \< 0.05; \*\*\*p \< 0.001; \*\*\*\*p \< 0.0001, hypergeometric test).\
(F) Violin plot for the H3K36me3 ChIP signal at ±50 nt of the 5^′^ (SS5) and 3^′^ (SS3) splice sites of the alternatively skipped exons in WT (white) and *Fmr1* KO (red) hippocampus tissue (p \< 0.05, K-S test for significance). See also [Figures S5E](#SD1){ref-type="supplementary-material"} and [S5F](#SD1){ref-type="supplementary-material"}.\
(G) Model for FMRP-mediated alterations in H3K36me3 marks on the chromatin and alternative splicing of transcripts in the hippocampus.\
See also [Table S3](#SD4){ref-type="supplementary-material"}.](nihms-1581010-f0008){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                                                        SOURCE                                 IDENTIFIER
  ---------------------------------------------------------------------------------------------------------- -------------------------------------- --------------------------------------------------------------------
  Antibodies                                                                                                                                        
  SETD2 Rabbit pAb-Polyclonal Antibodies                                                                     ABclonal                               Cat\# A11271; RRID: AB_2758486
  Lamin A/C Mouse Monoclonal Antibody (4A7)                                                                  Thermo Fisher                          Cat\# 14-9688-80; RRID: AB_2572956
  HRP conjugated antimouse secondary antibody                                                                Jackson Immunoresearch                 Cat\# 115-035-174; RRID: AB_2338512
  Rabbit polyclonal to Lamin B1                                                                              Abcam                                  Cat\# ab16048; RRID: AB_443298
  Anti-FMRP Rabbit polyclonal antibody                                                                       Abcam                                  Cat\# ab17722; RRID: AB_2278530
  HRP conjugated mouse anti-rabbit secondary antibody                                                        Jackson Immunoresearch                 Cat\# 211-032-171; RRID: AB_2339149
  Anti-α-Tubulin mouse Monoclonal antibody                                                                   Sigma                                  Cat\# T5168; RRID: AB_477579
  Anti-Rpl4 mouse monoclonal antibody                                                                        Proteintech                            Cat\# 67028--1-Ig
  Recombinant Anti-RENT1/hUPF1 antibody \[EP4682\]                                                           Abcam                                  Cat\# 133564
  Anti-MAP2 mouse monoclonal Antibody, clone AP20                                                            Millipore                              Cat\# AB5543; RRID: AB_571049
  Anti-eEF2 polyclonal rabbit Antibody                                                                       Cell Signaling Technology              Cat\# 2332; RRID: AB_10693546
  Anti- GAPDH (14C10) Rabbit monocloanal Antibody                                                            Cell Signaling Technology              Cat\# 2118; RRID: AB_561053
  Anti-MRPS18B Rabbit Polyclonal Antibody                                                                    Proteintech                            Cat\# 16139--1-AP; RRID: AB_2146368
  Anti-S6 Ribosomal Protein (5G10) Rabbit monoclonal antibody                                                Cell Signaling Technology              Cat\# 2217; RRID: AB_331355
  Anti-IgG mouse polyclonal antibody                                                                         Sigma                                  Cat\# 12--371; RRID: AB_145840
  Anti-Histone H3 (tri methyl K36) Rabbit polyclonal antibody                                                Abcam                                  Cat\# ab9050; RRID: AB_306966
  Chemicals, Peptides, and Recombinant Proteins                                                                                                     
  Cycloheximide solution                                                                                     Sigma                                  Cat\#C4859
  homoHarringtonine                                                                                          LKT laboratories                       Cat\#H0169--5
  Turbo DNaseI                                                                                               Ambion                                 Cat\#AM2238
  RNase A                                                                                                    Sigma                                  Cat\#R4875
  RNase T1                                                                                                   Thermo Fisher Scientific               Cat\#EN0542
  SUPERase In RNase inhibitor                                                                                Ambion                                 Cat\#AM2694
  RiboZero                                                                                                   Illumina                               Cat\#MRZG12324
  5 nm miRCat®−33 Conversion Oligos Pack15nm                                                                 IDT                                    Cat\#51-01-13-10
  SuperScript III                                                                                            Invitrogen                             Cat\#18080--044
  CircLigase                                                                                                 Epicenter                              Cat\#CL4115K
  Dynabeads MyOne Streptavidin C1                                                                            Invitrogen                             Cat\#65001
  KAPA Library Amplification Kit                                                                             Kapa Biosystems                        Cat\#KK2611
  AMPure XP beads                                                                                            Beckman Coulter                        Cat\#A63880
  NextSeq 500/550 High Output Kit v2 (75bp single-end runs)                                                  Illumina                               Cat\#FC-404--2005
  NextSeq 500/550 High Output Kit v2 (80bp pair-end runs)                                                    Illumina                               Cat\#FC-404--2002
  NEXTflex® Rapid Directional qRNA-Seq Kit (24 barcodes) - Set A/B                                           biooscientific                         Cat\#NOVA-5130--03D
  Critical Commercial Assays                                                                                                                        
  Qubit RNA HS Assay Kit                                                                                     Fisher scientific                      Cat\#Q32852
  Deposited Data                                                                                                                                    
  Raw and analyzed data                                                                                      This paper                             GEO: GSE143333
  Mouse reference genome NCBI build 38,mm10                                                                  Genome Reference Consortium            <https://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/mouse/>
  Experimental Models: Cell Lines                                                                                                                   
  Immortalized Mouse Embryonic Fibroblasts (MEFs)                                                            C57BL/6N wild-type or *Fmr1* KO mice   NA
  Experimental Models: Organisms/Strains                                                                                                            
  Mouse C57BL/6 wild-type                                                                                    Jackson lab                            Cat\# JAX:000664; RRID: IMSR_JAX:000664
  Fmr1^tm1Cgr^/Fmr1^tm1Cgr^ Mus musculus, backcrossed for more than 10 generations on a C57BL/6 background   Dr. Stephen T. Warren                  Cat\# 2665400; RRID: MGI:2665400
  Oligonucleotides                                                                                                                                  
  See [Table S1](#SD2){ref-type="supplementary-material"}, sheet 5                                           NA                                     NA
  Software and Algorithms                                                                                                                           
  DolphinNext                                                                                                [@R89]                                 NA
  clusterProfiler (3.10.1)                                                                                   [@R88]                                 NA
  hclust                                                                                                     [@R20]                                 NA
  pheatmap                                                                                                   [@R43]                                 NA
  anota2seq (1.0.0)                                                                                          [@R59]                                 NA
  SICER v1.1                                                                                                 [@R87]                                 NA
  rMATS package v3.2.5                                                                                       [@R73]                                 NA
  deepTools                                                                                                  [@R66]                                 NA

###### Highlights

-   Loss of FMRP reduces ribosome stalling on specific mRNAs, including Setd2

-   Increased SETD2 protein alters H3K36me3 marks in FMRP-deficient hippocampus

-   Alternative splicing is dysregulated in FMRP-deficient hippocampus

-   Altered H3K36me3 and splicing occur on genes and transcripts linked to autism
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